Delving into the Latest Updates on Ulviprubart with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

ABC 008, ABC-008, ABC008

Target

KLRG1

Mechanism

KLRG1 inhibitors(killer cell lectin like receptor G1 inhibitors)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [3]

Active Indication

Myositis, Inclusion BodyLarge Granular Lymphocytic Leukemia

Inactive Indication-

Originator Organization

Abcuro, Inc.Startup

Active Organization

Abcuro, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

RegulationOrphan Drug (US), Orphan Drug (EU)

Login to view timeline

Gene Sequence

Sequence Code 682558281H

Source: *****

Sequence Code 682558534L

Source: *****

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:
* Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR
* Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.

Start Date21 Oct 2024

Sponsor / Collaborator

Abcuro, Inc.Startup

NCT05721573 / Active, not recruitingPhase 2/3

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Start Date28 Feb 2023

Sponsor / Collaborator

Abcuro, Inc.Startup

[+1]

NCT05532722 / Active, not recruitingPhase 1/2

A Study of ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Start Date28 Sep 2022

Sponsor / Collaborator

Abcuro, Inc.Startup

100 Clinical Results associated with Ulviprubart

Login to view more data

100 Translational Medicine associated with Ulviprubart

Login to view more data

100 Patents (Medical) associated with Ulviprubart

Login to view more data

1

Literatures (Medical) associated with Ulviprubart

28 Jun 2019·Journal of microbiology and biotechnologyQ4 · ENGINEERING & TECHNOLOGY

Isolation and Characterization of Novel Chlorella Species with Cold Resistance and High Lipid Accumulation for Biodiesel Production

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Kang, Nam Kyu ; Lee, Bongsoo ; Kim, Eun Kyung ; Park, Won-Kun ; Koh, Hyun Gi ; Chang, Yong Keun ; Suh, William

Chlorella spp. are green algae that are found across wide-ranging habitats from deserts to arctic regions, with various strains having adapted to survive under diverse environmental conditions. In this study, two novel Chlorella strains (ABC-002, ABC-008) were isolated from a freshwater lake in South Korea during the winter season and examined for possible use in the biofuel production process. The comparison of ABC-002 and ABC-008 strains with Chlorella vulgaris UTEX265 under two different temperatures (10°C, 25°C) revealed their cold-tolerant phenotypes as well as high biomass yields. The maximum quantum yields of UTEX25, ABC- 002, and ABC-008 at 10°C were 0.5594, 0.6747, and 0.7150, respectively, providing evidence of the relatively higher cold-resistance capabilities of these two strains. Furthermore, both the biomass yields and lipid content of the two novel strains were found to be higher than those of UTEX265; the overall lipid productivities of ABC-002 and ABC-008 were 1.7 ~ 2.8 fold and 1.6 ~ 4.2 fold higher compared to that of UTEX265, respectively. Thus, the high biomass and lipid productivity over a wide range of temperatures indicate that C. vulgaris ABC-002 and ABC-008 are promising candidates for applications in biofuel productions via outdoor biomass cultivation.

16

News (Medical) associated with Ulviprubart

11 Nov 2024

·www.businesswire.com

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm E.T. Piper Sandler 36th Annual Healthcare Conference: Presentation on December 3, 2024, at 4:10 pm E.T. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

Immunotherapy

29 Aug 2024

·www.businesswire.com

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Morgan Stanley 22 nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T. Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

Immunotherapy

31 Jul 2024

·www.businesswire.com

Abcuro Appoints Sarah Boyce to its Board of Directors

NEWTON, Mass.--( BUSINESS WIRE )--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life sciences industry. “We are excited to welcome Sarah as a member of the Board and her experience will be instrumental as we focus on advancing ulviprubart in the ongoing Phase 3 MUSCLE trial for the treatment of inclusion body myositis,” said Mark Pruzanski, M.D., Chairman of the Board of Directors. “Sarah has extensive expertise in global product development, rare diseases and commercialization having helped bring over 20 products to market.” Ms. Boyce currently serves as the President and Chief Executive Officer of Avidity Biosciences, a publicly traded biotechnology company developing novel therapies for muscle wasting and other rare diseases. Prior to Avidity, she was President of Akcea Therapeutics and previously in her career held executive roles in business development and global operations for leading life sciences companies, including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and F. Hoffmann-La Roche AG. Ms. Boyce was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and one of the Fiercest Women in Life Sciences. She currently serves as a member of the Board of Directors at OmniAb and Contineum Therapeutics. Ms. Boyce holds a BSc (Hons) degree in microbiology from the University of Manchester, England. “I am thrilled to join Abcuro’s board at this critical point in the Company’s journey,” said Ms. Boyce. “I look forward to collaborating with the management team, providing guidance and sharing my expertise as the company progresses towards potential regulatory approval and readiness for potential commercialization.” About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com .

Executive ChangePhase 3Immunotherapy

100 Deals associated with Ulviprubart

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myositis, Inclusion Body	Phase 3	US	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	AU	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	BE	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	CA	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	FR	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	DE	Abcuro, Inc.Startup	28 Feb 2023
Myositis, Inclusion Body	Phase 3	GB	Abcuro, Inc.Startup	28 Feb 2023
Large Granular Lymphocytic Leukemia	Phase 2	US	Abcuro, Inc.Startup	28 Sep 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04659031 (ABC008-IBM-101, EULAR2022)	Phase 1	Myositis, Inclusion Body large granular lymphocytes (LGLs)	6	ABC008 0.1 mg/kg	lhivbajhrj(ladeixkhna) = One unrelated serious AE of fall with muscle tear in a C1 participant with a prior history of falls occurred vzyjnhnhoj (knekdsxfqo )	-	01 Jun 2022
				ABC008 0.5 mg/kg